Video

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Author(s):

Anthony Mato, MD

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
David L. Porter, MD
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Jean L. Koff, MD, MS
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Changchun Deng, MD, PhD
Related Content
Sanjal Desai, MD, medical oncologist, Mayo Clinic; assistant professor, medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
May 28th 2024

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Sanjal Desai, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
May 24th 2024

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Bita Fakhri, MD, MPH
May 7th 2024

Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL

Matthew S. Davids, MD, MMSc
May 6th 2024

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL